Table 1 BCMA-targeted CAR T clinical trials in multiple myeloma
From: Recent updates on CAR T clinical trials for multiple myeloma
Registration number (reference) | Phase | Dosage | No. of patients | Responses |
|---|---|---|---|---|
NCT02215967 (49) | 1 | 0.3–9.0 × 106 CAR+T cells/kg | 12 | sCR: 1; VGPR:2; PR:1; SD:8 |
NCT02658929 (51) | 1 | 50–800 × 106 CAR+ T cells | 33 | sCR:12; CR:3; VGPR:9; PR:4; SD:4; PD:1 |
NCT03274219 (52) | 1 | 150 × 106 CAR+ T cells | 8 | sCR: 1; VGPR: 3; PR: 2 MRD negative: 3 |
NCT03090659 (55) | 1/2 | 0.07–2.1 × 106 CAR+ T cells/kg | 57 | CR: 39; VGPR: 3; PR: 8; MRD negative: 36; ORR: 88% |
ChiCTR-ONH-17012285 (53) | 1 | 0.21–1.52 × 106 CAR+ T cells/kg | 17 | sCR: 13; VGPR: 2; ORR: 88.2% NR: 1 |
NCT03430011 (58) | 1/2 | 50–150 × 106 CAR+ T cells | 19 | sCR: 2; CR: 1; VGPR: 2; PR: 2; MR: 1 |
NCT03915184 (59) | NA | 0.5–1.8 × 108 CAR+ T cells | 16 | CR: 2; PR: 4; VGPR: 6 ORR: 100% |
NCT03070327 (61) | 1 | 72–818 × 106 CAR+ T cells | 11 | VGPR: 2; ORR: 64% |
ChiCTR1800018137 (64) | 1 | 1.0–6.0 × 106 CAR+ T cells/kg | 9 | CR:4; VGPR:1; PR: 4; ORR: 100% |
NCT02546167 (65) | 1 | 1–50 × 107 CAR+T cells | 25 | sCR: 1; CR: 1; VGPR: 5; PR: 5 |
NCT03288493 (67) | 1 | 48–430 × 106 CAR+ T cells | 12 | sCR: 1; nCR: 1; VGPR: 1; PR: 2 |
NCT03338972 (69) | 1 | 5–15 × 107 CAR+ T cells | 7 | ORR:100% |